Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • How big is the problem?
    • How we drive change
    • Our story
  • Featured insights
    • The latest at the Foundation
    • The latest at the Foundation
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • Become a catalyst
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
  • Achievements so far
    • The Foundation's impact
    • The Foundation's impact
  • News
  • Our team
  • Our impact
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us
Publications

Lack of access to medicine is a major driver of drug resistance. How can pharma take action?

The antibiotic market is unstable, with fragile supply chains and tough market conditions. This report sets out how these factors limit the development of a robust go-to-market model for such products. It features six case studies where companies and their partners are using a combination of access strategies to cut through the complexity and address access at a local level.

Date

27 October 2022

Download the full report

Antimicrobial resistance (AMR) is rising faster than expected. In 2019 alone, 1.27 million people died of drug-resistant infections, most of them in low- and middle-income countries (LMICs). Resistant infections can rapidly spread without appropriate access to essential antibiotics and antifungals. 

Yet, the issue of responsibly providing access for people living in resource-poor settings has been largely overlooked. This report identifies six new case studies of pharmaceutical companies that are making antibiotics and antifungals more widely available in low- and middle-income countries. Companies can use this study to understand the tools that are available to them to address access effectively. Other stakeholders may also use this study to understand systemic factors that may be preventing companies from prioritising access. 

What's in the report:

  • Why we need access: The world’s poorest countries experience the greatest rates of infectious disease and the highest levels of antibiotic resistance, but suffer the biggest gaps in access to the right treatments. Without appropriate access, AMR increases. 

  • What can companies do? A wide range of strategies are available to companies for improving access appropriately and sustainably. This report examines and illustrates these.

  • State of play: What the market looks like for companies looking to bring antibiotics and antifungals to more people, which includes challenges with the go-to-market model for off-patent/generic and on-patent medicines.

  • Case studies: 6 case studies that show how pharmaceutical companies used access strategies to make off-patent/generic and on-patent antibiotics and antifungals available in LMICS, including Nigeria, India, South Africa and Ghana. 

  • What's next? Tailored recommendations for pharmaceutical companies - including generic medicine manufacturers and research-based companies - and other stakeholders.

Lack of access to medicine is a major driver of drug resistance. How can pharma take action?

Download

This paper is published as part of the Antimicrobial Resistance Research Programme. The programme takes an in-depth look at how the pharmaceutical industry is responding to the growing challenge of drug-resistant infections. The case studies, discussion and recommendations in this study have been drawn from research published in the 2021 AMR Benchmark, as well as from interviews held with companies and experts in the AMR field. This is the first of three stand-alone studies that the AMR Research Programme will publish in 2022-2024.

Fatema Rafiqi

Research Programme Manager

frafiqi@accesstomedicinefoundation.org

Get in touch

News

Read the news at the Foundation
Featured News

Expert panel in The Hague connects Dutch, European and global efforts to tackle AMR

06 July 2022
News

Signs of progress by pharma against superbugs, yet little movement to address access

18 November 2021

The Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Copyright 2004 - 2022 Access to Medicine Foundation - All Rights Reserved